ReviewCytokine & growth factor reviews2018
Armed oncolytic viruses: A kick-start for anti-tumor immunity.
Review in Cytokine & growth factor reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis.Journal of virology · 2025Pooled it
- Chemokine-Armed Oncolytic Viruses: Engineering Immune Cell Trafficking to Transform the Tumor Microenvironment.Pharmaceutics · 2026Review
- Oncolytic Virotherapy and Immunogenic Cell Death: Mechanisms, Platforms, and Clinical Translation.Viruses · 2026Review
- Oncolytic human herpesvirus for cancer therapy.Molecular biology reports · 2026Review
- Advancements in intratumoral therapies for liver tumors.Frontiers in oncology · 2026Review
- A novel GM-CSF-encoding oncolytic adenovirus induces profound autophagy and promotes viral replication to enhance anti-tumor efficacy.Cancer gene therapy · 2025Article
- Genome-Wide Screening Reveals the Oncolytic Mechanism of Newcastle Disease Virus in a Human Colonic Carcinoma Cell Line.Viruses · 2025Article
- Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.Nature biomedical engineering · 2025Article
- From infection to tumor: genetic evidence of viral antibody immune response' role in urologic cancer development.Discover oncology · 2025Article
- New characteristics of cancer immunotherapy: trends in viral tumor immunotherapy with influenza virus-based approaches.Journal of Zhejiang University. Science. B · 2025Review
- Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Article
- Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors.Frontiers in immunology · 2025Review
- Advances in preclinical and clinical studies of oncolytic virus combination therapy.Frontiers in oncology · 2025Review
- Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines.Clinical and experimental medicine · 2024Review
- Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus.Cancer gene therapy · 2024Article
- The biological roles of CD47 in ovarian cancer progression.Cancer immunology, immunotherapy : CII · 2024Review
- OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.International journal of molecular sciences · 2024Review
- Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity.Nature communications · 2024Article
- Immune Cytolytic Activity and Strategies for Therapeutic Treatment.International journal of molecular sciences · 2024Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses (OVs), viruses that specifically result in killing tumor cells, represent a promising class of cancer therapy. Recently, the focus in the OV therapy field has shifted from their direct oncolytic effect to their immune stimulatory effect. OV therapy can function as a "kick start" for the antitumor immune response by releasing tumor associated antigens and release of inflammatory signals. Combining OVs with immune modulators could enhance the efficacy of both immune and OV therapies. Additionally, genetic engineering of OVs allows local expression of immune therapeutics, thereby reducing related toxicities. Different options to modify the tumor microenvironment in combination with OV therapy have been explored. The possibilities and obstacles of these combinations will be discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.